Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 3/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL1636830 | 0.98 | SMN1; SMN2 (0.69) | SMN1; SMN2HTTHSD17B10TSHRPOLB | |
| SCHEMBL1829347 | 0.83 | SMN1; SMN2 (1.00) | SMN1; SMN2HTTHSD17B10TSHRPOLB | |
| SCHEMBL4594749 | 0.83 | SMN1; SMN2 (0.55) | SMN1; SMN2HTTHSD17B10TSHRPOLB | |
| Methoxymethane SCHEMBL18550632 | 0.83 | SMN1; SMN2 (0.62) | SMN1; SMN2HTTHSD17B10TSHRPOLB | |
| Hydrochloric Acid SCHEMBL7250096 | 0.82 | SMN1; SMN2 (0.97) | SMN1; SMN2HTTHSD17B10TSHRPOLB | |
| Bromide SCHEMBL15825194 | 0.82 | SMN1; SMN2 (0.54) | SMN1; SMN2HTTHSD17B10TSHRPOLB | |
| SCHEMBL16086229 | 0.81 | SMN1; SMN2 (0.52) | SMN1; SMN2HTTHSD17B10TSHRPOLB | |
| SCHEMBL15522867 | 0.81 | SMN1; SMN2 (0.47) | SMN1; SMN2HTTHSD17B10TSHRPOLB | |
| SCHEMBL14549193 | 0.81 | SMN1; SMN2 (0.51) | SMN1; SMN2HTTHSD17B10TSHRPOLB | |
| SCHEMBL15581574 | 0.81 | ALDH1A1 (0.50) | SMN1; SMN2HTTHSD17B10ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118255746-A | Selective CDK12/13 inhibitors and uses thereof | 南京圣和药业股份有限公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20240092770-A1 | Heterocycle RMB39 Modulators | RECURSION PHARMACEUTICALS, INC. | 2024-03-21 | — | — | US | disclosed |
| WO-2024039689-A1 | HETEROCYCLE RBM39 MODULATORS | RECURSION PHARMACEUTICALS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| EP-4275759-A2 | QUINOLINE DERIVATIVES AS CHROMOBOX (CBX) PROTEIN INHIBITORS FOR TREATING CANCER | Dana-Farber Cancer Institute, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3515449-B1 | QUINOLINE DERIVATIVES AS CHROMOBOX (CBX) PROTEIN INHIBITORS FOR TREATING CANCER | DANA FARBER CANCER INST INC (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| WO-2022095989-A1 | P300 INHIBITORS AND USE THEREOF IN MEDICINE | 贝达药业股份有限公司 | 2022-05-12 | — | — | WO | disclosed |
| WO-2021203025-A1 | 1 H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1 H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021129817-A1 | PYRIMIDINE-BASED COMPOUND HAVING INHIBITORY EFFECT OF KETOHEXOKINASE (KHK) | 南京明德新药研发有限公司 | 2021-07-01 | — | — | WO | disclosed |
| CN-1267431-C | Substituted quinazoline derivatives and their use as inhibitors | ASTRAZENECA AB (SE) | 2006-08-02 | — | — | CN | disclosed |
| WO-2006036266-A1 | THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| CN-1753889-A | Quinazoline compounds | ASTRAZENECA AB (SE) | 2006-03-29 | — | — | CN | disclosed |
| US-20060046987-A1 | Substituted quinazoline derivatives and their use as inhibitors | ASTRAZENECA AB (SE) | 2006-03-02 | — | — | US | disclosed |
| US-20060035908-A1 | Thienopyrimidines useful as Aurora kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. | 2006-02-16 | — | — | US | disclosed |
| US-6919338-B2 | Substituted quinazoline derivatives and their use as inhibitors of aurora-2 kinase | ASTRAZENECA AB (SE) | 2005-07-19 | — | — | US | disclosed |
| CN-1496364-A | Substituted quinazoline derivatives and their use as inhibitors | — | 2004-05-12 | — | — | CN | disclosed |
| US-20030187002-A1 | Substituted quinazoline derivatives and their use as inhibitors | ASTRAZENECA AB (SE) | 2003-10-02 | — | — | US | disclosed |
| EP-1299381-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | AstraZeneca AB (SE) | 2003-04-09 | — | — | EP | disclosed |
| WO-2002000649-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | ASTRAZENECA AB (SE) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035908-A1 | Thienopyrimidines useful as Aurora kinase inhibitors | AURKA, AURKB, AURKC | SMN1; SMN2 3702/4885HTT 4544/4885HSD17B10 3860/4885 |
| US-20240092770-A1 | Heterocycle RMB39 Modulators | PRMT9, RCC2, RBBP9 | SMN1; SMN2 783/4885HTT 1714/4885HSD17B10 1115/4885 |
| US-20060046987-A1 | Substituted quinazoline derivatives and their use as inhibitors | AURKA, AURKB, AURKC | SMN1; SMN2 3417/4885HTT 4307/4885HSD17B10 3227/4885 |
| US-20030187002-A1 | Substituted quinazoline derivatives and their use as inhibitors | AURKA, AURKC, AURKB | SMN1; SMN2 3412/4885HTT 4535/4885HSD17B10 3022/4885 |
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINE1, SERPINA3 | SMN1; SMN2 3099/4885HTT 890/4885HSD17B10 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.